Saroglitazar (magnesium)
CAS No. : 1639792-20-3
| Size | Price | Stock |
|---|---|---|
| 1mg | $65 | In-stock |
| 5mg | $165 | In-stock |
| 10mg | $250 | In-stock |
| 25mg | $430 | In-stock |
| 50mg | $560 | In-stock |
| 100mg | $730 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-19937A |
| M.Wt: | 901.42 |
| Formula: | C50H56MgN2O8S2 |
| Purity: | >98 % |
| Solubility: | DMSO : 125 mg/mL (ultrasonic) |
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively. IC50 & Target:EC50: 0.65 pM (hPPARα, HepG2 cell); 3 nM (hPPARγ, HepG2 cell)[1] In Vivo: In db/db mice, 12-day treatment with Saroglitazar (0.01-3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Saroglitazar (magnesium)
- Cat. No.:
- HY-19937A
- Quantity:
Your information is safe with us.